Abstract
BackgroundTofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis (RA).ObjectivesTo evaluate the malignancies that occurred in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have